People

Emmanuel Caeymaex

theodorus.be

Theodorus publishes Emmanuel Caeymaex with the following specifically scoped affiliation: Investment Committee member — Pharma Expert, UCB (committee/LP representative affiliation, not an employment claim). Fund IV is a distinct 2018 investment vehicle, and shared-platform directory listings do not independently establish a direct Fund IV employment contract or exact appointment date. Own published biographical background: Pharma Expert, UCB Emmanuel CAEYMAEX is Executive Vice President and Immunology Patient Value Unit Head at UCB. He leads the understanding of patient needs, the development and commercialization of solutions. Over the last 20 years Emmanuel has been instrumental in advancing UCB’s transformation into a global biopharma company focused on patients with severe diseases. The legacy Theodorus UCB title is superseded by UCB’s current primary directory: Executive Vice President, Patient Evidence, effective January2026.